Advances in antiviral therapy in dermatology

Dermatologic Clinics

Volumn 16, Issue 2, 1998, Pages 409-420

  Evans, T Y ^a   Tyring, S K ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; CIDOFOVIR; DELAVIRDINE; DIDANOSINE; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; IDOXURIDINE; IMIQUIMOD; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PENCICLOVIR; RIBAVIRIN; RIMANTADINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIFLURIDINE; VIDARABINE; VIRUS VECTOR; ZIDOVUDINE;

ABSTINENCE; ANTIVIRAL ACTIVITY; BLOOD SAMPLING; CONDOM; FOOD AND DRUG ADMINISTRATION; HEALTH PROGRAM; HUMAN; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; VACCINATION; VIRUS TRANSMISSION;

EID: 0031900136     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70022-X     Document Type: Article

References (78)

1. I. Arany P.L. Rady S.K. Tyring Interferon treatment enhances the expression of underphosphorylated (biologically active) retinoblastoma protein in human papilloma virus infected cells through the inhibitory TGFβ/IFNβ cytokine pathway Antiviral Res 23 1994 131 141
2. S. Baron S.K. Tyring W.R. Fleischmann The interferons: Mechanisms of action and clinical applications JAMA 266 1991 1375 1383
3. 3 [abstract Th.B 6019]. In Program and Abstracts of the XI International Conference on AIDS. Vancouver, British Columbia, July 1996.
4. K.R. Beutner Patient-applied podofilox for treatment of genital warts Lancet 8 1989 31
5. S. Boyles S.W. Key AIDS hope does not mean cure is imminent Antiviral Weekly 10 1996 5
6. Cameron W, Sun E, Markowitz M, et al: Combination use of ritonavir and saquinavir in HIV-infected patients: Preliminary safety and activity data. In Program and Abstracts of the 11th International Conference on AIDS [abstract Th.B 934]. Vancouver, British Columbia, July 1996.
7. N. Cammack Lamivudine in the therapy of HIV infection International Antiviral News 4 1996 127 128
8. C.C.J. Carpenter M.A. Fischl S.M. Hammer Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel JAMA 276 1996 146 154
9. Centers for Disease Control and Prevention Case-control study of HIV seroconversion in health care workers after percutaneous exposure to HIV infected blood—France, United Kingdom, and United States, January 1988–August 1994 MMWR 44 1995 929 933
10. Y. Chang F. Cesarman M.S. Pessin Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma Science 266 1994 1865
11. K.F. Chopra S.K. Tyring Current antiviral therapy in the treatment of human immunodeficiency virus infections Semin Cutan Med Surg 16 1997 224 234
12. Collier AC, Coombs RW, Timpone J, et al: Comparative study of Ro 31-8959 and zidovudine (ZDV) vs ZDV and zalcitabine (DDC). In Program and Abstracts of the 10th International Conference on AIDS [abstract 058B]. Yokohama, Japan, August 1994.
13. L.M. Cowsert M.C. Fox G. Zone In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: Potential treatment for genital warts Antimicrob Agents Chemother 37 1993 171
14. Craig IC, Duncan IB, Roberts NA, et al: Ro 31-8959, an inhibitor of HIV proteinase, appears relatively refractory to the generation of virus mutants with reduced sensitivity. In Program and Abstracts of the Ninth International Conference on AIDS [abstract PO-A26-0649]. Berlin, Germany, June 1993.
15. R.T. D'Aquila M.D. Hughes V.A. Johnson Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: A randomized, double-blind, placebo-controlled trial Ann Intern Med 124 1996 1019 1030
16. S.G. Deeks M. Smith M. Holodniy HIV-1 protease inhibitors: A review for clinicians JAMA 277 1997 145 153
17. Duncan IB, Jacobsen H, Owen S, et al: Reduced HIV sensitivity during treatment with the proteinase inhibitor saquinavir. In Program and Abstracts of the Third Conference on Retroviruses and Opportunistic Infections [abstract 155]. Washington, DC, January– February 1996.
18. 3 following at least 6 months of zidovudine. Presented at the American Society for Microbiology 34th ICAAC. Orlando, Florida, October 1994.
19. A.E. Friedman-Kien L.J. Eron M. Conant Natural interferon alfa for treatment of condyloma acuminata JAMA 259 1988 533 538
20. Gathe J, Burkhardt B, Hawley P, et al: A randomized phase II study of Viracept, a novel HIV protease inhibitor, used in combination with stavudine vs stavudine alone [abstract M.B 413]. In Program and Abstracts of the XI International Conference on AIDS. Vancouver, British Columbia, July 1996.
21. J. Gerberding Is antiretroviral treatment after percutaneous HIV exposure justified? Ann Intern Med 113 1990 740 746
22. D.K. Goette Topical chemotherapy with 5-fluorouracil J Am Acad Dermatol 6 1981 633
23. L.H. Goldberg R. Kaufman T.O. Kurtz The acyclovir study group. Long-term suppression of recurrent genital herpes with acyclovir: A 5-year benchmark Arch Dermatol 129 1993 582 587
24. R.H. Goldshmidt A. Moy Antiretroviral drug treatment for HIV/AIDS Am Fam Physician 54 1996 574 580
25. Gulick R, Mellors J, Havlir D, et al: Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine [abstract LB7]. In Program and Abstracts of the Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, February 1996.
26. S.M. Hammer D.A. Katzenstein M.D. Hughes A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200–500 per cubic millimeter N Engl J Med 335 1996 1081 1090
27. D.V. Havlir D.D. Richman Viral dynamics of HIV: Implications for drug development and therapeutic strategies Ann Intern Med 124 1996 984 994
28. D.R. Henrard J.F. Phillips L.R. Muenz Natural history of HIV-1 cell free viremia JAMA 274 1995 554 558
29. K. Herne R. Cirelli P. Lee Advances in antiviral therapy Current Opinion in Dermatology 3 1996 195 201
30. J.C. Huff J.L. Drucker A. Clemmer Effect of oral acyclovir on pain resolution in herpes zoster. A reanalysis J Med Virol Suppl 1 1993 93 96
31. J.L. Jackson R. Gibbons G. Meyer The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia Arch Intern Med 157 1997 909 912
32. H. Jacobsen I.C. Yasargil D.L. Winslow Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959 Virology 206 1995 527 534
33. M.H. Kaplan N. Sadick N.S. McNutt Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS) J Am Acad Dermatol 16 1987 485
34. Katlama C: Second International Congress on Drug Therapy of HIV Infection [abstract 2831]. Glasgow, Scotland, November 1994.
35. D.A. Katzenstein S.M. Hammer M.D. Hughes The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200-500 CD4 cells per cubic millimeter N Engl J Med 335 1996 1091 1098
36. V.S. Kitchen C. Skinner K. Ariyoshi Safety and activity of saquinavir in HIV infection Lancet 345 1995 952 955
37. Lalezari J, Haubrich R, Burger HU, et al: Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase, SQV) plus HIVID (zalcitabine, ddC) [abstract LB.B. 6033]. In Program and Abstracts of the XI International Conference on AIDS. Vancouver, British Columbia, July 1996.
38. J.P. Lalezari R.J. Stagg M.S. Jaffe A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC) J.A. Mills P.A. Volberding L. Corey Antiviral Chemotherapy 4. New Directions for Clinical Application and Research 1996 Plenum Press New York 105 115
39. rd International Congress on drug therapy in HIV infection: Darwinian evolution and genetic misadventures Research Initiative Treatment Action 2 1996 11 14
40. J.A. Levy Surrogate markers in AIDS research, is there truth in numbers? JAMA 276 1996 161 162
41. th ICAAC meeting. San Francisco, California, September 1995.
42. K. Luzuriaga Y. Bryson P. Krogstad Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection N Engl J Med 336 1997 1343 1349
43. K. Luzuriaga Y. Bryson G. McSherry Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children J Infect Dis 174 1996 713 721
44. Massari F, Conant M, Mellors J, et al: Phase II open label, randomized study of the triple combination of indinavir, zidovudine (ZDV) and didanosine (DDI) versus indinavir alone and ZDV/DDI in antiretroviral naïve patients [abstract 200]. In Program and Abstracts of the Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, February 1996.
45. C.K. McDonald D.R. Kuritzkes Human immunodeficiency virus type 1 protease inhibitors Arch Intern Med 157 1997 951 959
46. J.W. Mellors L.A. Kingsley C.R. Rinaldo Jr Quantification of HIV-1 RNA in plasma predicts outcome after seroconversion Ann Intern Med 122 1995 573 579
47. O. Memar R. Cirelli P. Lee Cutaneous manifestations of HIV-1 infection J Am Podiatr Med Assoc 85 1995 361 374
48. H. Mitsuya K.J. Weinhold P.A. Furman Double-blind, placebo-controlled trial comparing long-term suppression with short term oral acyclovir therapy for management of recurrent genital herpes Am J Med 85 suppl 2A 1988 20 25
49. th International Conference on AIDS. Vancouver, British Columbia, July 1996.
50. News in Brief FDA's fast delavirdine approval International Antiviral News 5 1997 87
51. L. Perrin B. Hirschel Combination therapy in primary HIV infection Antiviral Res 29 1996 87 89
52. J.M. Pluda T.P. Cooley J.S.G. Montaner A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infections J Infect Dis 171 1995 1438
53. R.C. Reichman D. Oakes W. Bonnez Treatment of condyloma acuminatum with three different interferon-α preparations administered parenterally: A double-blind, placebo-controlled trial J Infect Dis 162 1990 1270
54. R. Reid M.D. Greenberg D.J. Pizzuti Superficial laser vulvectomy, V: Surgical debulking is enhanced by adjuvant systemic interferon Am J Obstet Gynecol 166 1992 815
55. E. Richman HIV Infection and AIDS update: Advances in clinical care Internal Medicine World Report 11 3 1996 5 7
56. D.D. Richman M.A. Fischl M.H. Grieco The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex N Engl J Med 317 1987 192 197
57. Saag AS, Hardy WD: Early treatment urged [newsletter]. In HIV Information Network Fax Newsletter. November 1996.
58. S.L. Sacks F. Aoki F. Diaz-Mitoma Patient-initiated, twice daily oral famciclovir for the early recurrent genital herpes JAMA 276 1996 44 49
59. W.S. Sawchuk Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: Detection and protection J Am Acad Dermatol 21 1989 41
60. J.M. Schapiro M.A. Winters F. Stewart The effect of high-dose saquinavir on viral load and CD4 T-cell counts in HIV-infected patients Ann Intern Med 124 1996 1039 1050
61. R. Shuurman M. Nijhuis R. van Leeuwen Rapid changes in human immune deficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine J Infect Disease 171 1995 1431
62. S.L. Spruance Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis J Med Virol 1 suppl 1993 27 32
63. rd ICAAC meeting. New Orleans, Louisiana, October, 1993.
64. S.L. Spruance T.L. Rea C. Thoming Penciclovir cream for the treatment of herpes simplex labialis JAMA 277 1997 1374 1379
65. R.A. Torres M.R. Barr K.I. McIntyre A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease Int J STD AIDS 6 1995 19 26
66. th Annual Meeting. San Francisco, California, March, 1997.
67. A. Thandi S.K. Tyring Newer aspects of herpesvirus infections M.V. Dahl Current Opinions in Dermatology 1997 Rapid Science Publishers Philadelphia 42 50
68. S.K. Tyring Viral infections involving the skin D.D. Richman R.J. Whitley F.G. Hayden Clinical Virology 1997 Churchill Livingstone Inc New York 127 147
69. S. Tyring R.A. Barbarash J. Nahlik Famciclovir for the treatment of acute herpes zoster: Effects on acute disease and postherpetic neuralgia Ann Intern Med 123 1995 89 96
70. E. Van Cutsem R. Snoeck M. Van Ranst Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl) cytosine J Med Virol 45 1995 230 235
71. P.A. Volberding S.W. Lagakos M.A. Koch Zidovudine in asymptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter N Engl J Med 322 1990 941 949
72. A.J. Wagstaff D. Faulds L. Goak Acyclovir, a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy Drugs 47 1994 153 205
73. th October, 1994 ICAAC Orlando, Florida
74. A. Wald J. Zeh G. Barnum Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir Ann Intern Med 124 1996 8 15
75. R.J. Whitley The biology of B virus (cercopithecine virus) B. Roizman R.J. Whitley C. Lopez The Human Herpesviruses 1993 Raven Press New York 317
76. P. Wynn Class of AIDS drugs boost combination therapy approach Dermatology Times 17 1996 33
77. K. Yamanishi T. Okuno K. Shiraki Identification of human herpesvirus-6 as a causal agent for exanthem subitum Lancet 1 1988 1065
78. M.J. Zalla W.P. Su A.F. Fransway Dermatologic manifestations of human immunodeficiency virus infection Mayo Clin Proc 67 1992 1089